Bulletin of the National Research Centre

Table 3 Predicted drug-likeness based on the Lipinski’s rule including bioavailability (BA) and synthetic accessibility (SA) of compound 28, designed compounds and vemurafenib

From: Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties

SN	Mol. wt	HBA	HBD	Log P	TPSA (Å²)	BA	SA
28	496.310	6	2	4.850	98.000	0.550	3.430
N1	545.770	6	3	4.790	124.020	0.550	3.600
N2	571.330	9	2	4.650	153.050	0.170	3.930
N3	662.460	10	3	5.090	198.370	0.170	4.470
Vem	489.920	6	2	4.970	100.300	0.550	3.380

Mol. wt. molecular weight, HBA hydrogen bond acceptor, HDB hydrogen bond donor, TPSA topological polar surface area

Back to article page